Fractionated versus standard continuous light delivery in interstitial photodynamic therapy of dunning prostate carcinomas

Clinical Cancer Research

Volumn 13, Issue 24, 2007, Pages 7496-7505

  Xiao, Zhengwen ^a,b   Halls, Steve ^b   Dickey, Dwayne ^a   Tulip, John ^a   Moore, Ronald B ^a,b,c  

^a UNIVERSITY OF ALBERTA   (Canada)

^b CROSS CANCER INSTITUTE   (Canada)

^c UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

1,3 DIENE C,D DIETHYLENE GLYCOL ESTER A; BENZOPORPHYRIN DERIVATIVE; GLASS FIBER; QLT 0074; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COMPUTER SYSTEM; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DOSE RESPONSE; FRACTIONATION; ILLUMINATION; MALE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROSTATE TUMOR; RADIATION DOSE; RAT; STANDARD; SURVIVAL; TUMOR VOLUME;

ANIMALS; MAGNETIC RESONANCE IMAGING; MALE; PHOTOCHEMOTHERAPY; PROSTATIC NEOPLASMS; RATS;

EID: 37549021119     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-1561     Document Type: Article

References (35)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2007. CA Cancer J Clin 2007;57:43-66.
2. Carter HB. Prostate cancers in men with low PSA levels - must we find them? N Engl J Med 2004;350:2292-4.
3. D'Amico AV, Chen MH, Roehl KA, Catalona WJ. Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N Engl J Med 2004;351:125-35.
4. Stamey TA, Caldwell M, McNeal JE, Nolley R, Hemenez M, Downs J. The prostate antigen era in the United States is over for prostate cancer: what happened in the last 20 years? J Urol 2004;172:1297-301.
5. Doughery TJ, Gomer CJ, Henderson BW, et al. Photodynamic therapy. J Natl Cancer Inst 1998;90:889-905.
6. Nathan TR, Whitelaw BE, Chang SC, et al. Photodynamic therapy for prostate cancer recurrence after radiotherapy: a phase I study. J Urol 2002;168:1427-32.
7. Gibson SL, Van Der Meid KR, Murant RS, Raubertas RF, Hiff R. Effects of various photoradiation regimens on the antitumor efficacy of photodynamic therapy for R3230AC mammary carcinoma. Cancer Res 1990;50:7236-41.
8. Henderson BW, Busch TM, Vaughan LA, et al. Photofrin photodynamic therapy can significantly deplete or preserve oxygenation in human basal cell carcinomas during treatment, depending on fluence rate. Cancer Res 2000;60:525-9.
9. Sitnik TM, Hampton JA, Henderson BW. Reduction of tumor oxygenation during and after photodynamic therapy in vivo: effects of fluence rate. Br J Cancer 1998;77:1386-94.
10. Tromberg BJ, Orenstein A, Kimel S, et al. In vivo tumor oxygen tension measurements for the evaluation of the efficiency of photodynamic therapy. Photochem Photobiol 1990;52:375-85.
11. Fingar VH, Wieman TJ, Wiehle SA, Cerrito PB. The role of microvascular damage in photodynamic therapy: the effect of treatment on vessel constriction, permeability, and leukocyte adhesion. Cancer Res 1992;52:4914-21.
12. Moore RB, Chapman JD, Mercer JR, et al. Measurement of PDT-induced hypoxia in Dunning prostate tumors by iodine-123-iodoazomycin arabinoside. J Nucl Med 1993;34:405-13.
13. Xiao Z, Dickey D, Owen RJ, Tulip J, Moore RB. Interstitial photodynamic therapy of the canine prostate using intra-arterial administration of photosensitizer and computerized pulsed light delivery. J Urol 2007;178:308-13.
14. Chen Q, Huang Z, Chen H, Shapiro H, Beckers J, Hetzel FW. Improvement of tumor response by manipulation of tumor oxygenation during photodynamic therapy. Photochem Photobiol 2002;76:197-203.
15. Iinuma S, Schomacker KT, Wagnieres G, et al. In vivo fluence rate and fractionation effects on tumor response and photobleaching: photodynamic therapy of two photosensitizers in an orthotopic rat tumor model. Cancer Res 1999;59:6164-70.
16. 2 tension measurements. Cancer Res 1991;51:3316-22.
17. 2 dynamic during photodynamic therapy with verteporfin. Photochem Photobiol 2001;74:700-6.
18. Chen Q, Chen H, Hetzel FW. Tumor oxygenation changes post-photodynamic therapy. Photochem Photobiol 1996;63:128-31.
19. Kennedy SD, Szczepaniak LS, Gibson SL, Hilf R, Foster TH, Bryant RG. Quantitative MRI of Gd-DTPA uptake in tumor: response to photodynamic therapy. Magn Reson Med 1994;31:292-301.
20. Su MY, Samoszuk MK, Wang J, Nalcioglu O. Assessment of protamine-induced thrombosis of tumor vessels for cancer therapy using dynamic contrast-enhanced MRI. NMR Biomed 2002;15:106-13.
21. Gross S, Gilead A, Scherz A, Neeman M, Salomon Y. Monitoring photodynamic therapy of solid tumors online by BOLD-contrast MRI. Nat Med 2003;9:1327-31.
22. Isaacs JT. Development and characteristics of the available animal model systems for the study of prostate cancer. In: Coffey DS, Bruchovsky N, Gardener WA, Resnick MI, Cur JP, editors. Current concepts and approaches to the study of prostate cancer. New York: Alan R. Liss;1987. p. 513-76.
23. Thorndyke C, Meeker BE, Thomas G, Lakey WH, McPhee MS, Chapman JD. The radiation sensitivities of R3327-H and R3327-ATrat prostate adenocarcinomas. J Urol 1985;134:191-8.
24. Chapman JD, McPhee MS, Walz N, et al. Nuclear magnetic resonance spectroscopy and sensitizer-adduct measurements of photodynamic therapy-induced ischemia in solid tumors. J Natl Cancer Inst 1991;83:1650-9.
25. Xiao Z, Tamimi Y, Brown K, Tulip J, Moore R. Interstitial photodynamic therapy in subcutaneously implanted urologic tumors in rats after intravenous administration of 5-aminolevulinic acid. Urol Oncol 2002;7:125-32.
26. Granville DJ, Hunt DWC. Porphyrin-mediated photosensitization - taking the apoptosis fast lane. Curr Opin Drug Discov Devel 2000;3:232-43.
27. Richter AM, Waterfield E, Jain AK, Canaan AJ, Allison BA, Levy JG. Liposomal delivery of a photosensitizer, benzoporphyrin derivative monoacid ring A (BPD), to tumor tissue in a mouse tumor model. Photochem Photobiol 1993;57:1000-6.
28. Richter AM, Waterfield E, Jain AK, et al. Photosensitizing potency of structural analogues of benzoporphyrin derivatives (BPD) in a mouse tumor model. Br J Cancer 1991;63:87-93.
29. Zhao D, Ran S, Constantinescu A, Hahn EW, Mason RP. Tumor oxygen dynamics: correlation of in vivo MRI with histological findings. Neoplasia 2003;5:308-18.
30. Fei B, Wang H, Muzic RF, Jr., et al. Deformable and rigid registration of MRI and microPET images for photodynamic therapy of cancer in mice. Med Phys 2006;33:753-60.
31. Foster TH, Murant RS, Bryant RG, Knox RS, Gibson SL, Hilf R. Oxygen consumption and diffusion effects in photodynamic therapy. Radiat Res 1991;126:296-303.
32. Zilberstein J, Bromberg A, Frantz A, et al. Light-dependent oxygen consumption in bacteriochlorophyllserine-treated melanoma tumors: on-line determination using a tissue-inserted oxygen microsensor. Photochem Photobiol 1997; 65:1012-9.
33. Henderson BW, Busch TM, Snyder JW. Fluence rate as a modulator of PDT mechanisms. Lasers Surg Med 2006;38:489-93.
34. Busch TM. Local physiological changes during photodynamic therapy. Lasers Surg Med 2006;38:494-9.
35. Dickey DJ, Partridge K, Moore RB, Tulip J. Light dosimetry for multiple cylindrical diffusing source for the use in photodynamic therapy. Phys Med Biol 2004;49:3197-208.